Amkay Products

Why is Amkay Products Ltd falling/rising?

As of 24-Jun, Amkay Products Ltd's stock price is Rs 52.61, down -2.57% today and -14.80% year-to-date, significantly underperforming against the Sensex. The stock is trading below its moving averages and has seen a substantial drop in investor interest, indicating a bearish trend.

As of 24-Jun, Amkay Products Ltd is experiencing a decline in its stock price, currently at Rs 52.61, which reflects a change of -1.39 or -2.57%. The stock has underperformed significantly today, lagging behind its sector by -3.09%. It opened with a loss of -2.57% and reached an intraday low of Rs 52.61, indicating a lack of upward momentum during the trading session.<BR><BR>Over the past week, the stock has decreased by -7.69%, while the benchmark Sensex has only fallen by -0.21%. This trend continues over a one-month period, where Amkay Products Ltd has dropped -13.75%, contrasting sharply with the Sensex's gain of +2.09%. Year-to-date, the stock is down -14.80%, while the Sensex has declined by -9.66%. <BR><BR>Additionally, the stock is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which typically indicates a bearish trend. Investor participation has also decreased, with delivery volume falling by -70.59% compared to the 5-day average, suggesting reduced interest from investors. Overall, these factors contribute to the ongoing decline in Amkay Products Ltd's stock price.

Which are the latest news on Amkay Products?

What does Amkay Products do?

Amkay Products Ltd is a micro-cap company in the healthcare services industry, recently converted to a public limited company. It has a market cap of INR 48 Cr, with key metrics including a P/E ratio of 21.00 and a return on equity of 8.76%.

Overview: <BR>Amkay Products Ltd operates in the healthcare services industry and is classified as a micro-cap company.<BR><BR>History: <BR>Amkay Products Limited was originally incorporated as "Amkay Products Private Limited" in 2007. It was later converted into a Public Limited Company, with the name change to "Amkay Products Limited" occurring on August 28, 2023. Revenue and profit data for the latest quarter are not available.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: INR 48 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 21.00 <BR>Industry P/E: 92 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.03 <BR>Return on Equity: 8.76% <BR>Price-to-Book: 1.90 <BR><BR>Contact Details: <BR>Address: Not available <BR>Phone: Not available <BR>Email: Not available <BR>Website: Not available

How big is Amkay Products?

As of 10th June, Amkay Products Ltd has a market capitalization of 48.00 Cr, classifying it as a Micro Cap company. There is no valid financial data available for the latest four quarters, but as of March 2025, Shareholder's Funds are 24.07 Cr and Total Assets are 29.63 Cr.

As of 10th June, <BR><BR>Market Cap: Amkay Products Ltd has a market capitalization of 48.00 Cr, categorizing it as a Micro Cap company.<BR><BR>Recent Quarterly Performance: There is no valid financial data available for the latest four quarters, including Net Sales and Net Profit.<BR><BR>Balance Sheet Snapshot: The latest reporting period is March 2025, with Shareholder's Funds amounting to 24.07 Cr and Total Assets valued at 29.63 Cr.

Who are the peers of the Amkay Products?

Amkay Products' peers include Choksi Laborator, Royal Sense, Bandaram Pharma, Shree Pacetronix, KMS Medisurgi, N G Industries, Samsrita Labs, and GKB Ophthalmics. Key metrics show varying management risks, growth rates, and returns, with Amkay Products having a 1-year return of 28.21%.

Peers: The peers of Amkay Products are Choksi Laborator, Royal Sense, Bandaram Pharma, Shree Pacetronix, KMS Medisurgi, N G Industries, Samsrita Labs, and GKB Ophthalmics.<BR><BR>Quality Snapshot: Excellent management risk is observed at Royal Sense and N G Industries, while Good management risk is found at Shree Pacetronix, Amkay Products, and the rest. Below Average management risk is noted at Choksi Laborator, Bandaram Pharma, and GKB Ophthalmics. Average management risk is present at KMS Medisurgi. Growth is Excellent at Royal Sense, Good at Choksi Laborator, Bandaram Pharma, Shree Pacetronix, and GKB Ophthalmics, while Below Average growth is seen at Amkay Products, KMS Medisurgi, and N G Industries. Samsrita Labs does not qualify for growth. Capital Structure is Good for Royal Sense, Shree Pacetronix, Amkay Products, KMS Medisurgi, and N G Industries, while Below Average is noted for Choksi Laborator and Bandaram Pharma, and the rest do not qualify.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Shree Pacetronix at 63.71%, while the lowest is Royal Sense at -57.28%. Amkay Products has a 1-year return of 28.21%, which is significantly higher than Royal Sense but lower than Shree Pacetronix. Additionally, Choksi Laborator, Royal Sense, Bandaram Pharma, Shree Pacetronix, N G Industries, and GKB Ophthalmics all have negative six-month returns.

When is the next results date for Amkay Products Ltd?

The next results date for Amkay Products Ltd is 28 May 2026.

The next results date for Amkay Products Ltd is scheduled for 28 May 2026.

How has been the historical performance of Amkay Products?

Amkay Products has shown fluctuating performance over the past five years, with net sales increasing to 38.39 Cr in March 2025 from 31.07 Cr in March 2024, alongside improvements in profits and total assets, indicating a positive trend in recent years.

Answer:<BR>The historical performance of Amkay Products shows a fluctuating trend in net sales and profits over the past five years.<BR><BR>Breakdown:<BR>Amkay Products reported net sales of 38.39 Cr in March 2025, an increase from 31.07 Cr in March 2024 and 27.86 Cr in March 2023, although it was lower than the 40.70 Cr in March 2021. The total operating income followed a similar pattern, reaching 38.39 Cr in March 2025. The company's total expenditure, excluding depreciation, was 34.26 Cr in March 2025, up from 27.74 Cr in March 2024. Operating profit (PBDIT) increased to 5.45 Cr in March 2025 from 4.58 Cr in March 2024, while profit before tax rose to 4.30 Cr in March 2025 from 3.50 Cr in March 2024. Profit after tax also improved to 3.34 Cr in March 2025 compared to 2.63 Cr in March 2024. The company's total assets increased to 29.63 Cr in March 2025 from 17.74 Cr in March 2024, with total liabilities also rising to 29.63 Cr. The cash flow from financing activities showed a positive trend with a net cash inflow of 1.00 Cr in March 2025, indicating improved liquidity. Overall, while Amkay Products experienced some fluctuations, the recent years show a positive trajectory in sales and profitability.

Is Amkay Products overvalued or undervalued?

As of September 15, 2025, Amkay Products is considered undervalued with a PE ratio of 13.61 and an EV to EBITDA of 11.27, making it more attractive compared to its peers, despite a year-to-date stock performance decline of -15.87% against the Sensex's 4.67% return.

As of 15 September 2025, the valuation grade for Amkay Products has moved from very expensive to very attractive, indicating a significant shift in its market perception. The company is currently assessed as undervalued. Key ratios supporting this conclusion include a PE ratio of 13.61, an EV to EBITDA of 11.27, and a ROE of 13.88%. <BR><BR>In comparison to its peers, Amkay Products stands out with a much lower PE ratio than Poly Medicure (56.25) and Blue Jet Health (34.63), both categorized as very expensive. This suggests that Amkay Products offers a more favorable valuation relative to its competitors. Despite a recent decline in stock performance compared to the Sensex, where it has underperformed with a year-to-date return of -15.87% against the Sensex's 4.67%, the underlying financial metrics indicate that the company is positioned well for potential growth.

Who are the top shareholders of the Amkay Products?

The top shareholder of Amkay Products is Kashyap Pravin Mody, holding 30.95%, with no pledged promoter holdings. The highest public shareholder is Rakesh Khanna at 1.11%, while individual investors collectively own 23.23% of the shares.

The top shareholders of Amkay Products primarily consist of the promoters, with Kashyap Pravin Mody holding the highest stake at 30.95%. There are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors (FIIs) holding shares. The highest public shareholder is Rakesh Khanna, who owns 1.11% of the shares. Additionally, individual investors collectively hold 23.23% of the company's shares.

What is the technical trend for Amkay Products?

As of May 29, 2025, Amkay Products is in a mildly bearish trend, indicated by daily moving averages and weekly Bollinger Bands, despite a mildly bullish weekly MACD and mixed signals from Dow Theory, with the stock underperforming relative to the Sensex.

As of 29 May 2025, the technical trend for Amkay Products has changed from sideways to mildly bearish. The current stance is mildly bearish, driven by the daily moving averages indicating bearish momentum and the weekly Bollinger Bands also reflecting a bearish outlook. The weekly MACD shows a mildly bullish signal, but this is countered by the overall bearish sentiment from the daily indicators. The Dow Theory presents a mixed view with a mildly bearish weekly signal and a mildly bullish monthly signal. The stock's performance relative to the Sensex shows significant underperformance across multiple time frames, further supporting the bearish outlook.

Has Amkay Products declared dividend?

No Dividend History Available